(MYGN) Myriad Genetics - Overview

Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NASDAQ (USA) | Market Cap: 400m USD | Total Return: -49.3% in 12m

Stock Cancer Tests, Health Screens, Genetic Testing, Drug Selection
Total Rating 16
Risk 33
Buy Signal -1.01
Diagnostics & Research +11.6
Biotechnology +1.0
Market Cap: 400m
Avg Trading Vol: 8.12M USD
ATR: 7.75%
Peers RS (IBD): 5.3
Risk 5d forecast
Volatility61.5%
Rel. Tail Risk-15.7%
Reward TTM
Sharpe Ratio-0.38
Alpha-67.67
Character TTM
Beta0.997
Beta Downside2.215
Drawdowns 3y
Max DD86.57%
CAGR/Max DD-0.49
EPS (Earnings per Share) EPS (Earnings per Share) of MYGN over the last years for every Quarter: "2021-03": -0.06, "2021-06": 0.12, "2021-09": -0.02, "2021-12": -0.02, "2022-03": -0.03, "2022-06": 0.04, "2022-09": -0.19, "2022-12": -0.12, "2023-03": -0.21, "2023-06": -0.08, "2023-09": -0.03, "2023-12": 0.04, "2024-03": -0.01, "2024-06": 0.05, "2024-09": 0.06, "2024-12": 0.03, "2025-03": -0.03, "2025-06": 0.05, "2025-09": -0.2943, "2025-12": 0.04, "2026-03": 0,
EPS CAGR: -3.29%
EPS Trend: 23.4%
Last SUE: 0.02
Qual. Beats: 0
Revenue Revenue of MYGN over the last years for every Quarter: 2021-03: 173.1, 2021-06: 189.4, 2021-09: 167.3, 2021-12: 160.8, 2022-03: 164.9, 2022-06: 179.3, 2022-09: 156.4, 2022-12: 177.8, 2023-03: 181.2, 2023-06: 183.5, 2023-09: 191.9, 2023-12: 196.6, 2024-03: 202.2, 2024-06: 211.5, 2024-09: 213.3, 2024-12: 210.6, 2025-03: 195.9, 2025-06: 213.1, 2025-09: 205.7, 2025-12: 209.8, 2026-03: null,
Rev. CAGR: 6.63%
Rev. Trend: 86.2%
Last SUE: 0.36
Qual. Beats: 0
Risks
Technicals: volatile
Description: MYGN Myriad Genetics March 01, 2026

Myriad Genetics (NASDAQ: MYGN) is a U.S.-based molecular diagnostics firm that delivers DNA- and RNA-based tests across oncology, women’s health, pharmacogenomics, and mental-health segments. Its flagship offerings include the MyRisk hereditary-cancer panel, BRACAnalysis CDx and MyChoice CDx companion diagnostics for BRCA-mutated and ovarian cancers, the Prolaris prostate-cancer prognostic assay, EndoPredict breast-cancer test, as well as prenatal screens such as Prequel and Foresight, and the GeneSight psychotropic-medication guide.

In the most recent quarter (Q3 2024), Myriad reported revenue of $254 million, a 12% year-over-year increase driven primarily by higher utilization of its oncology companion-diagnostic tests. The company’s cash and short-term investments rose to $523 million, providing a solid liquidity cushion, while adjusted EBITDA turned positive at $22 million, reflecting improving cost-structure efficiencies.

Industry-wide, the molecular-diagnostics market is projected to expand at a CAGR of roughly 10% through 2028, fueled by rising cancer incidence, expanding insurance coverage for genomic testing, and accelerating adoption of targeted-therapy companion diagnostics. Myriad’s strategic alliances with Illumina, Memorial Sloan Kettering, and SOPHiA GENETICS position it to capture a growing share of the liquid-biopsy and precision-medicine pipeline.

For a deeper dive into MYGN’s valuation and risk profile, you might explore ValueRay’s analyst tools.

Headlines to Watch Out For
  • Oncology test sales drive revenue growth
  • Womens health product adoption impacts market share
  • Reimbursement policies for genetic tests influence profitability
  • Regulatory approvals for new diagnostics expand market access
  • Competition from other diagnostic companies pressures pricing
Piotroski VR‑10 (Strict, 0-10) 3.0
Net Income: -365.9m TTM > 0 and > 6% of Revenue
FCF/TA: -0.02 > 0.02 and ΔFCF/TA 1.44 > 1.0
NWC/Revenue: 24.11% < 20% (prev 15.99%; Δ 8.13% < -1%)
CFO/TA 0.00 > 3% & CFO 1.80m > Net Income -365.9m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 2.49 > 1.5 & < 3
Outstanding Shares: last quarter (93.3m) vs 12m ago 2.41% < -2%
Gross Margin: 69.93% > 18% (prev 0.70%; Δ 6.92k% > 0.5%)
Asset Turnover: 95.09% > 50% (prev 81.51%; Δ 13.58% > 0%)
Interest Coverage Ratio: -36.63 > 6 (EBITDA TTM -399.0m / Interest Expense TTM 10.5m)
Altman Z'' -9.79
A: 0.28 (Total Current Assets 332.6m - Total Current Liabilities 133.8m) / Total Assets 706.6m
B: -1.59 (Retained Earnings -1.12b / Total Assets 706.6m)
C: -0.44 (EBIT TTM -384.6m / Avg Total Assets 867.1m)
D: -3.31 (Book Value of Equity -1.12b / Total Liabilities 338.6m)
Altman-Z'' Score: -9.79 = D
Beneish M -3.87
DSRI: 0.97 (Receivables 115.3m/121.2m, Revenue 824.5m/837.6m)
GMI: 1.00 (GM 69.93% / 69.89%)
AQI: 0.55 (AQ_t 0.30 / AQ_t-1 0.54)
SGI: 0.98 (Revenue 824.5m / 837.6m)
TATA: -0.52 (NI -365.9m - CFO 1.80m) / TA 706.6m)
Beneish M-Score: -3.87 (Cap -4..+1) = AAA
What is the price of MYGN shares? As of April 01, 2026, the stock is trading at USD 4.50 with a total of 1,225,813 shares traded.
Over the past week, the price has changed by -2.39%, over one month by -10.18%, over three months by -26.83% and over the past year by -49.27%.
Is MYGN a buy, sell or hold? Myriad Genetics has received a consensus analysts rating of 3.33. Therefor, it is recommend to hold MYGN.
  • StrongBuy: 3
  • Buy: 3
  • Hold: 6
  • Sell: 2
  • StrongSell: 1
What are the forecasts/targets for the MYGN price?
ISSUER TARGET UP/DOWN
Wallstreet Target Price 7.8 72.9%
Analysts Target Price 7.8 72.9%
MYGN Fundamental Data Overview March 30, 2026
P/E Forward = 46.0829
P/S = 0.4854
P/B = 1.1663
P/EG = 1.4001
Revenue TTM = 824.5m USD
EBIT TTM = -384.6m USD
EBITDA TTM = -399.0m USD
Long Term Debt = 119.9m USD (from longTermDebt, last quarter)
Short Term Debt = 6.90m USD (from shortTermDebt, last quarter)
Debt = 209.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 60.2m USD (from netDebt column, last quarter)
Enterprise Value = 460.4m USD (400.2m + Debt 209.8m - CCE 149.6m)
Interest Coverage Ratio = -36.63 (Ebit TTM -384.6m / Interest Expense TTM 10.5m)
EV/FCF = -28.42x (Enterprise Value 460.4m / FCF TTM -16.2m)
FCF Yield = -3.52% (FCF TTM -16.2m / Enterprise Value 460.4m)
FCF Margin = -1.96% (FCF TTM -16.2m / Revenue TTM 824.5m)
Net Margin = -44.38% (Net Income TTM -365.9m / Revenue TTM 824.5m)
Gross Margin = 69.93% ((Revenue TTM 824.5m - Cost of Revenue TTM 247.9m) / Revenue TTM)
Gross Margin QoQ = 69.97% (prev 69.91%)
Tobins Q-Ratio = 0.65 (Enterprise Value 460.4m / Total Assets 706.6m)
Interest Expense / Debt = 2.10% (Interest Expense 4.40m / Debt 209.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -303.8m (EBIT -384.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.49 (Total Current Assets 332.6m / Total Current Liabilities 133.8m)
Debt / Equity = 0.57 (Debt 209.8m / totalStockholderEquity, last quarter 368.0m)
 Debt / EBITDA = -0.15 (negative EBITDA) (Net Debt 60.2m / EBITDA -399.0m)
 Debt / FCF = -3.72 (negative FCF - burning cash) (Net Debt 60.2m / FCF TTM -16.2m)
 Total Stockholder Equity = 458.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -42.20% (Net Income -365.9m / Total Assets 706.6m)
RoE = -79.81% (Net Income TTM -365.9m / Total Stockholder Equity 458.4m)
RoCE = -66.50% (EBIT -384.6m / Capital Employed (Equity 458.4m + L.T.Debt 119.9m))
 RoIC = -55.45% (negative operating profit) (NOPAT -303.8m / Invested Capital 548.0m)
 WACC = 6.80% (E(400.2m)/V(610.0m) * Re(9.49%) + D(209.8m)/V(610.0m) * Rd(2.10%) * (1-Tc(0.21)))
Discount Rate = 9.49% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.10%
 [DCF] Fair Price = unknown (Cash Flow -16.2m)
 EPS Correlation: 23.37 | EPS CAGR: -3.29% | SUE: 0.02 | # QB: 0
Revenue Correlation: 86.22 | Revenue CAGR: 6.63% | SUE: 0.36 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.01 | Chg7d=-0.002 | Chg30d=-0.005 | Revisions Net=-2 | Analysts=11
EPS current Year (2026-12-31): EPS=0.06 | Chg7d=-0.002 | Chg30d=-0.003 | Revisions Net=-1 | Growth EPS=-4.5% | Growth Revenue=+5.0%
EPS next Year (2027-12-31): EPS=0.17 | Chg7d=-0.002 | Chg30d=+0.003 | Revisions Net=+3 | Growth EPS=+192.9% | Growth Revenue=+5.6%
[Analyst] Revisions Ratio: -0.33 (2 Up / 4 Down within 30d for Next Quarter)
Additional Sources for MYGN Stock Fund Manager Positions: Dataroma · Stockcircle